ATE306931T1 - Unterdrückung von veränderungen in zusammenhang mit beta-amyloid bei alzheimer - Google Patents

Unterdrückung von veränderungen in zusammenhang mit beta-amyloid bei alzheimer

Info

Publication number
ATE306931T1
ATE306931T1 AT98961894T AT98961894T ATE306931T1 AT E306931 T1 ATE306931 T1 AT E306931T1 AT 98961894 T AT98961894 T AT 98961894T AT 98961894 T AT98961894 T AT 98961894T AT E306931 T1 ATE306931 T1 AT E306931T1
Authority
AT
Austria
Prior art keywords
beta
alzheimer
amyloid
suppression
changes associated
Prior art date
Application number
AT98961894T
Other languages
English (en)
Inventor
Howard L Weiner
Dennis J Selkoe
Original Assignee
Neuralab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26747618&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE306931(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neuralab Ltd filed Critical Neuralab Ltd
Application granted granted Critical
Publication of ATE306931T1 publication Critical patent/ATE306931T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)
  • Engine Equipment That Uses Special Cycles (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
AT98961894T 1997-12-03 1998-12-03 Unterdrückung von veränderungen in zusammenhang mit beta-amyloid bei alzheimer ATE306931T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6721997P 1997-12-03 1997-12-03
US7969798P 1998-03-27 1998-03-27
PCT/US1998/025694 WO1999027949A1 (en) 1997-12-03 1998-12-03 METHOD OF SUPPRESSING β-AMYLOID-RELATED CHANGES IN ALZHEIMER'S DISEASE

Publications (1)

Publication Number Publication Date
ATE306931T1 true ATE306931T1 (de) 2005-11-15

Family

ID=26747618

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98961894T ATE306931T1 (de) 1997-12-03 1998-12-03 Unterdrückung von veränderungen in zusammenhang mit beta-amyloid bei alzheimer

Country Status (8)

Country Link
EP (1) EP1033998B1 (de)
JP (2) JP2002511385A (de)
AT (1) ATE306931T1 (de)
AU (1) AU742970C (de)
CA (1) CA2312475C (de)
DE (2) DE1033998T1 (de)
ES (1) ES2253839T3 (de)
WO (1) WO1999027949A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997021728A1 (en) 1995-12-12 1997-06-19 Karolinska Innovations Ab PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID $g(b)
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
DE1033998T1 (de) * 1997-12-03 2001-05-23 Brigham And Women S Hospital B Methode zur unterdrückung von beta-amyloid-verwandten veränderungen in alzheimer
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US7060670B1 (en) 1999-05-05 2006-06-13 Neurochem (International) Limited Stereoselective antifibrillogenic peptides and peptidomimetics thereof
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
ATE286072T1 (de) 2000-05-22 2005-01-15 Univ New York Synthetische immunogene jedoch nicht amyloidogene peptide, die homolog zu amyloid beta sind und deren verwendung zur induktion einer immunantwort gegen amyloid beta und amyloidaggregate
WO2002003911A2 (en) 2000-07-07 2002-01-17 Lars Lannfelt Prevention and treatment of alzheimer's disease
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
US7264810B2 (en) 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
US7479482B2 (en) 2001-11-21 2009-01-20 New York University Synthetic immunogenic but non-deposit-forming polypeptides and peptides homologous to amyloid β, prion protein, amylin, α-synuclein, or polyglutamine repeats for induction of an immune response thereto
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
SI1524994T1 (sl) 2002-07-19 2011-08-31 Cytos Biotechnology Ag Sestavki cepiv, ki vsebujejo amiloidne beta 1-6 antigenske mreĹľe
AU2003303198A1 (en) 2002-12-19 2004-07-14 New York University Method for treating amyloid disease
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
GB0424563D0 (en) 2004-11-05 2004-12-08 Novartis Ag Organic compounds
CA2590337C (en) 2004-12-15 2017-07-11 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
RU2442793C2 (ru) 2005-11-30 2012-02-20 Эбботт Лэборетриз АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ
SG2014013437A (en) 2005-11-30 2014-07-30 Abbott Lab Monoclonal antibodies and uses thereof
NZ567888A (en) 2006-03-23 2010-08-27 Bioarctic Neuroscience Ab Improved protofibril selective antibodies and the use thereof
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
ES2498040T3 (es) 2007-07-27 2014-09-24 Janssen Alzheimer Immunotherapy Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
MX360403B (es) 2010-04-15 2018-10-31 Abbvie Inc Proteinas de union a amiloide beta.
JP6147665B2 (ja) 2010-08-14 2017-06-14 アッヴィ・インコーポレイテッド アミロイドベータ結合タンパク質
US9926353B2 (en) 2011-07-19 2018-03-27 New York University Immunotherapeutic modulation of amyloidogenic disease using non-fibrillogenic, non-amyloidogenic polymerized proteins and peptides
WO2013013056A1 (en) 2011-07-19 2013-01-24 New York University Method for treating amyloid disease
JP2016503410A (ja) * 2012-11-09 2016-02-04 スリーイー セラピューティクス コーポレイション３Ｅ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｘ線造影剤組成物およびそれを使用して炎症関連症状を治療する方法
KR102564384B1 (ko) 2014-07-10 2023-08-07 바이오악틱 에이비 개선된 Aβ 프로토피브릴 결합 항체

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223482A (en) * 1986-11-17 1993-06-29 Scios Nova Inc. Recombinant Alzheimer's protease inhibitory amyloid protein and method of use
JP2980677B2 (ja) * 1990-04-27 1999-11-22 マクマイケル，ジョン 不正常なアミロイドβタンパク質と関連する中枢神経系疾患状態の治療のための方法および組成物
WO1995031996A1 (en) * 1994-05-25 1995-11-30 Milkhaus Lab Materials and methods for treatment of plaquing diseases
AU6113896A (en) * 1995-06-05 1996-12-24 Brigham And Women's Hospital Use of oral tolerance to suppress both th1 and th2 immune re sponses and to suppress antibody production
WO1997018855A1 (en) * 1995-11-21 1997-05-29 Eduard Naumovich Lerner Device for enhanced delivery of biologically active substances and compounds in an organism
ZA97452B (en) * 1996-01-25 1997-08-15 Trinity College Dublin Streptococcus equi vaccine.
JPH09208485A (ja) * 1996-01-31 1997-08-12 Teijin Ltd ペプチド・蛋白質性薬物の水難溶性組成物
DE1033998T1 (de) * 1997-12-03 2001-05-23 Brigham And Women S Hospital B Methode zur unterdrückung von beta-amyloid-verwandten veränderungen in alzheimer

Also Published As

Publication number Publication date
AU1709999A (en) 1999-06-16
CA2312475C (en) 2010-08-03
AU742970B2 (en) 2002-01-17
EP1033998A1 (de) 2000-09-13
JP2002511385A (ja) 2002-04-16
WO1999027949A9 (en) 1999-09-10
JP2010215627A (ja) 2010-09-30
EP1033998B1 (de) 2005-10-19
EP1033998A4 (de) 2003-06-04
AU742970C (en) 2003-03-20
DE1033998T1 (de) 2001-05-23
DE69831971T2 (de) 2006-07-06
DE69831971D1 (de) 2006-03-02
WO1999027949A1 (en) 1999-06-10
CA2312475A1 (en) 1999-06-10
ES2253839T3 (es) 2006-06-01

Similar Documents

Publication Publication Date Title
ATE306931T1 (de) Unterdrückung von veränderungen in zusammenhang mit beta-amyloid bei alzheimer
EP0552256A4 (de)
GEP20053715B (en) Prevention and Treatment of Amyloidogenic Disease
DE69331409T2 (de) Oral 1alpha-hydroxyprevitamin d
WO1994027589A3 (en) Antidepressant dosage form
ATE338771T1 (de) Antagonisten des intestinotrophen glp-2 peptides
SE9703191D0 (sv) Medicament for improvement of duration of muscle function or treatment of muscle disorders or diseases
ATE234602T1 (de) Verabreichungsform zur abgabe von steigenden wirkstoffdosen
DE3875108D1 (de) Physiologisch aktives polypeptid und pharmazeutische komposition.
GR1000419B (el) Μορφη δοσολογιας για χορηγηση ανταγωνιστη του ασβεστιου.
IT1222395B (it) Composizione farmaceutica per somministrazione intranasale comprendente l'ormone ghrh,un agonista colinergico e/o un sale biliare
NO943288L (no) Anvendelse av pentoksyfyllin ved fremstilling av farmasöytiske preparater til behandling av granulomatöse og fibroserende lungesykdommer
TR200000455T2 (tr) Alzheimer hastalığının tedavisinde fankinonun kullanılması.
MX9707642A (es) Uso de 2-oxoindol-1-carboxamidas 3-sustituidas y sus sales de base farmaceuticamente aceptables para preparar composiciones para el tratamiento y prevencion de la enfermedad de alzheimer en mamiferos, incluyendo a humanos.
PT1150703E (pt) Terapia de esclerose multipla com chaperonina 10 e beta-interferao
BG103905A (en) New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine
DE69314586T2 (de) Arzneimittelzusammensetzung enthaltend TCF-II
MY112888A (en) Use of bradykinin antagonists for the preparation of medicaments for the treatment of virus diseases.
DE59410137D1 (de) Neue pharmazeutische zubereitungen zur oralen verabreichung enthaltend cyclosporin
DE69822234D1 (de) Verwendung von Olanzapin zur Herstellung eines Arzneimittels zur Neuroprotektion
TH19526A (th) วิธีการและสารผสมสำหรับรักษาโรคตับอักเสบชนิดออโตอิมมูน
MX9604539A (es) Aminoacidos modificados para la distribucion de farmaco.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties